Most buyers agree that its products are worth taking
Retatrutide, a triple agonist targeting gastric inhibitory polypeptide (GIP), GLP-1, and glucagon receptors, has achieved highly promising outcomes in its phase 2 trial [22], with weight loss up to 24%
In a recent study, only one-third of people who started a GLP-1 medication were still taking it at the one-year mark
Retrieved July 30, 2025, from 5
However, unlike endogenous GLP-1, which breaks down rapidly in the body, Sema has been chemically modified to be long-acting and resistant to enzymatic degradation
Potential Mechanism Underlying the Effects of GLP-1 RAs in Heart Failure GLP-1 RAs bind to GLP-1 receptors expressed in various tissues, including pancreatic beta cells, the kidneys, heart, brain and gastric mucosa, among other organs